苏葶止喘汤联合西医治疗小儿支气管哮喘急性发作期(痰热阻肺证) 38例

目的探讨苏葶止喘汤联合西医治疗小儿支气管哮喘急性发作期(痰热阻肺证)临床疗效。方法收集 2020年 2月至 2022年 3月河北省沧州中西医结合医院就诊的急性发作期的支气管哮喘病儿 78例，根据随机数字表法分为对照组与治疗组各 39例，对照组病儿给予硫酸沙丁胺醇、异丙托溴铵、布地奈德雾化吸入等西医治疗，治疗组在对照组基础上给予苏葶止喘汤治疗，观察两组治疗前后的临床疗效，症状缓解时间(咳痰消失时间、哮鸣音消失时间、咳嗽消失时间、喘息消失时间)肺功能指标［用力肺活量(FVC)第 1秒用力呼吸容积(FEV1)第 1秒用力呼气量占所有呼气量的比例(FEV1/FVC)最大呼气流量(，PEF)气中断流速( PEF25%)、、呼吸中期瞬间流速( PEF50%、)、呼吸后期瞬间流速( PEF75%)］血清炎症因子指、标［C反应蛋白(CRP)、呼、白细胞介素 -22(IL-22)、白细胞介素 -4(IL-4)］，Toll样受体 2(TLR2)Toll样受体 4(TLR4)，表达水平。结果治疗后治疗组总有效率 94.74%显著高于对照组 71.05%(P<0.05)；治疗组症状缓解时间快、于对照组( P<0.05)；治疗后两组 FVC、FEV1、FEV1/FVC、PEF、PEF25%、PEF50%、PEF75%值均较治疗前升高且治疗组高于对照组( P<0.05)；治疗后两组血清 CRP、IL-22、IL-4、TLR2、 TLR4水平均较治疗前降低，且治疗组 CRP［( 10.23±3.26)mg/L比( 15.25±5.37)mg/L］、 IL-22［( 37.13±9.84)ng/L比( 45.46±11.08) ng/L］、IL-4［(48.15±12.28)ng/L比( 56.07±14.36)ng/L］、 TLR2［(16.78±1.91)ng/L比( 21.15±2.08)ng/L］、 TLR4［(18.05±2.53)ng/L比

Suting Zhichuan decoction combined with western medicine in the treatment of acute exacerbation of bronchial asthma in children (phlegm-heat blocking lung syndrome):a report of 38 cases

Objective To explore the clinical efficacy of Suting Zhichuan decoction combined with western medicine in the treatment of acute exacerbation of bronchial asthma in children (phlegm-heat blocking lung syndrome). Methods A total of 78 children with acute bronchial asthma who were treated in Cangzhou Hospital of Integrated TCM-WM Hebei were collected from February 2020 toMarch 2022. According to the random number table method, they were assigned into a control group and a treatment group with 39 cas-es in each group. The control group was treated with salbutamol sulfate, ipratropium bromide, and budesonide aerosol inhalation, while the treatment group was given Suting Zhichuan decoction in addition to the western medicine therapy. Observation was made beforeand after treatment of the clinical efficacy, symptom relief time (the disappearance of expectoration, wheezing, cough, and pant), the pul-monary function indexes [forced vital capacity (FVC), forced expiratory volume in first second (FEV1), ratio of forced expiratory volumein first second to forced vital capacity (FEV1/FVC), peak expiratory flow (PEF), interrupted expiratory flow rate (PEF25%), instanta-neous flow rate in mid-respiratory phase (PEF50%), transient flow rate in late-respiratory phase (PEF75%)], serum inflammatory factor indexes [C-reactive protein (CRP), interleukin-22 (IL-22), interleukin-4 (IL-4)], and the expression levels of Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4) in the two groups.Results After treatment, the total effective rate of the treatment group was 94.74%,which was significantly higher than that of the control group (71.05%, P<0.05). The symptom relief time of the treatment group was shorter than that of the control group (P<0.05). The values of FVC, FEV1, FV1/FVC, PEF, PEF25%, PEF50%, and PEF75% after treat-ment were all higher than those before treatment, and the treatment group was higher than the control group (P<0.05). The values of CRP, IL-22, IL-4, TLR2, and TLR4 in both groups were decreased after treatment, and CRP [(10.23±3.26) mg/L vs. (15.25±5.37) mg/ L], IL-22 [(37.13±9.84) ng/L vs. (45.46±11.08) ng/L], IL-4 [(48.15±12.28) ng/L vs. (56.07±14.36) ng/L], TLR2 [(16.78±1.91) ng/L vs. (21.15±2.08) ng/L], TLR4 [(18.05±2.53) ng/L vs. (22.44±3.27) ng/L] were lower in the treatment group than the control group (P<0.05). Conclusion Sutin Zhichuan decoction combined with western medicine has a significant clinical effect in the treatment of acute exac-erbation of bronchial asthma in children.